Key Points

  • A recent trial showed increased risk of death or bleeding in neonates who received platelet transfusions for platelet counts above 25 × 109/L.

  • The current analysis reveals that these harmful effects occur in neonates with high, as well as low, baseline risk of death or bleeding.

Abstract

The Platelets for Neonatal Thrombocytopenia (PlaNeT-2) trial reported an unexpected overall benefit of a prophylactic platelet transfusion threshold of 25 × 109/L compared with 50 × 109/L for major bleeding and/or mortality in preterm neonates (7% absolute-risk reduction). However, some neonates in the trial may have experienced little benefit or even harm from the 25 × 109/L threshold. We wanted to assess this heterogeneity of treatment effect in the PlaNet-2 trial, to investigate whether all preterm neonates benefit from the low threshold. We developed a multivariate logistic regression model in the PlaNet-2 data to predict baseline risk of major bleeding and/or mortality for all 653 neonates. We then ranked the neonates based on their predicted baseline risk and categorized them into 4 risk quartiles. Within these quartiles, we assessed absolute-risk difference between the 50 × 109/L- and 25 × 109/L-threshold groups. A total of 146 neonates died or developed major bleeding. The internally validated C-statistic of the model was 0.63 (95% confidence interval, 0.58-0.68). The 25 × 109/L threshold was associated with absolute-risk reduction in all risk groups, varying from 4.9% in the lowest risk group to 12.3% in the highest risk group. These results suggest that a 25 × 109/L prophylactic platelet count threshold can be adopted in all preterm neonates, irrespective of predicted baseline outcome risk. Future studies are needed to improve the predictive accuracy of the baseline risk model. This trial was registered at www.isrctn.com as #ISRCTN87736839.

REFERENCES

REFERENCES
1.
Fustolo-Gunnink
SF
,
Huisman
EJ
,
van der Bom
JG
, et al
.
Are thrombocytopenia and platelet transfusions associated with major bleeding in preterm neonates? A systematic review
.
Blood Rev
.
2019
;
36
:
1
-
9
.
2.
Stanworth
SJ
,
Clarke
P
,
Watts
T
, et al;
Platelets and Neonatal Transfusion Study Group
.
Prospective, observational study of outcomes in neonates with severe thrombocytopenia
.
Pediatrics
.
2009
;
124
(
5
):
e826
-
e834
.
3.
Curley
A
,
Stanworth
SJ
,
Willoughby
K
, et al;
PlaNeT2 MATISSE Collaborators
.
Randomized Trial of Platelet-Transfusion Thresholds in Neonates
.
N Engl J Med
.
2019
;
380
(
3
):
242
-
251
.
4.
Fustolo-Gunnink
SF
,
Fijnvandraat
K
,
Putter
H
, et al
.
Dynamic prediction of bleeding risk in thrombocytopenic preterm neonates
.
Haematologica
.
2019
;
104
(
10
):
208595
.
5.
Ioannidis
JPA
,
Lau
J
.
The impact of high-risk patients on the results of clinical trials
.
J Clin Epidemiol
.
1997
;
50
(
10
):
1089
-
1098
.
6.
Kent
DM
,
Hayward
RA
.
Limitations of Applying Summary Results of Clinical Trials to Individual Patients: The Need for Risk Stratification
.
JAMA
.
2007
;
298
(
10
):
1209
-
1212
.
7.
Kent
DM
,
Nelson
J
,
Dahabreh
IJ
,
Rothwell
PM
,
Altman
DG
,
Hayward
RA
.
Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials
.
Int J Epidemiol
.
2016
;
45
(
6
):
2075
-
2088
.
8.
Curley
A
,
Venkatesh
V
,
Stanworth
S
, et al
.
Platelets for neonatal transfusion - study 2: a randomised controlled trial to compare two different platelet count thresholds for prophylactic platelet transfusion to preterm neonates
.
Neonatology
.
2014
;
106
(
2
):
102
-
106
.
9.
Collins
GS
,
Reitsma
JB
,
Altman
DG
,
Moons
KGM
.
Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement
.
BMJ
.
2015
;
350
:
g7594
.
10.
Steyerberg
EW
,
Vergouwe
Y
.
Towards better clinical prediction models: seven steps for development and an ABCD for validation
.
Eur Heart J
.
2014
;
35
(
29
):
1925
-
1931
.
11.
Steyerberg
EW
.
Clinical prediction models: a practical approach to development, validation and updating
.
New York, NY
:
Springer-Verlag
;
2009
.
12.
Bell
MJ
,
Ternberg
JL
,
Feigin
RD
, et al
.
Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging
.
Ann Surg
.
1978
;
187
(
1
):
1
-
7
.
13.
Harrell
FE
.
Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis
.
New York, NY
:
Springer-Verlag, Inc.
;
2010
.
14.
Kent
DM
,
Steyerberg
E
,
van Klaveren
D
.
Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects
.
BMJ
.
2018
;
363
:
k4245
.
15.
Dahabreh
IJ
,
Hayward
R
,
Kent
DM
.
Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidence
.
Int J Epidemiol
.
2016
;
45
(
6
):
2184
-
2193
.
16.
Rothwell
PM
,
Mehta
Z
,
Howard
SC
,
Gutnikov
SA
,
Warlow
CP
.
Treating individuals 3: from subgroups to individuals: general principles and the example of carotid endarterectomy
.
Lancet
.
2005
;
365
(
9455
):
256
-
265
.
17.
CBO
.
Blood Transfusion Guideline
.
Utrecht, The Netherlands
:
CBO (Centraal Begeleidingsorgaan voor de Intercollegiale Toetsing [National Organization for Quality Assurance])
;
2011
. .
18.
Liumbruno
G
,
Bennardello
F
,
Lattanzio
A
,
Piccoli
P
,
Rossetti
G
;
Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) Work Group
.
Recommendations for the transfusion of plasma and platelets
.
Blood Transfus
.
2009
;
7
(
2
):
132
-
150
.
19.
French Health Products Safety Agency
(Agence française de sécurité sanitaire des produits de santé [AFSSAPS]). Platelet transfusion: products, indications (Transfusion de plaquettes: produits, indications). Saint-Denis, France: AFSSAPS
2003
.
20.
Hayward
RA
,
Kent
DM
,
Vijan
S
,
Hofer
TP
.
Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis
.
BMC Med Res Methodol
.
2006
;
6
:
18
.
21.
Sun
X
,
Briel
M
,
Busse
JW
, et al
.
Credibility of claims of subgroup effects in randomised controlled trials: systematic review
.
BMJ
.
2012
;
344
:
e1553
.
22.
Wallach
JD
,
Sullivan
PG
,
Trepanowski
JF
,
Sainani
KL
,
Steyerberg
EW
,
Ioannidis
JP
.
Evaluation of evidence of statistical support and corroboration of subgroup claims in randomized clinical trials
.
JAMA Intern Med
.
2017
;
177
(
4
):
554
-
560
.
23.
Kent
DM
,
Rothwell
PM
,
Ioannidis
JPA
,
Altman
DG
,
Hayward
RA
.
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal
.
Trials
.
2010
;
11
:
85
.
24.
Kent
DM
,
Ruthazer
R
,
Selker
HP
.
Are some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset?
Stroke
.
2003
;
34
(
2
):
464
-
467
.
25.
Costa
F
,
van Klaveren
D
,
James
S
, et al;
PRECISE-DAPT Study Investigators
.
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials
.
Lancet
.
2017
;
389
(
10073
):
1025
-
1034
.
26.
Farooq
V
,
van Klaveren
D
,
Steyerberg
EW
, et al
.
Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II
.
Lancet
.
2013
;
381
(
9867
):
639
-
650
.
27.
Mulder
MJHL
,
Venema
E
,
Roozenbeek
B
, et al
.
Towards personalised intra-arterial treatment of patients with acute ischaemic stroke: a study protocol for development and validation of a clinical decision aid
.
BMJ Open
.
2017
;
7
(
3
):
e013699
.
28.
Venema
E
,
Mulder
MJHL
,
Roozenbeek
B
, et al
.
Selection of patients for intra-arterial treatment for acute ischaemic stroke: development and validation of a clinical decision tool in two randomised trials
.
BMJ
.
2017
;
357
:
j1710
.
You do not currently have access to this content.

Comments

0 Comments